ACAD vs EWTX
ACADIA Pharmaceuticals Inc. vs Edgewise Therapeutics, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
EWTX
Edgewise Therapeutics, Inc.
61
Buy
| Metric | ACAD | EWTX |
|---|
| AI Score |
69
|
61
|
| Price |
$29.41
|
$44.30
|
| P/E Ratio |
13.07×
|
-23.95×
|
| ROE |
31.9%
|
-32.1%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
0.0%
|
| Debt / Equity |
0.06×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
61.0
|
| Beta |
0.845
|
0.275
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus EWTX.
ACAD leads by 8 points.
ACAD scores 69/100 (Buy) versus EWTX at 61/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
EWTX Committee View
60% agreement
5 analysts
Positive signals support the current rating — vix regime is low -- calm backdrop supports risk-taking. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- Price-to-book of 5.0x prices in significant intangible value — Value
- ROE of only -39.0% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 23.8% signals elevated volatility — Risk